RESUMO
Pancreatic cancer is one of the most malignancy tumor in digestive system with extraordinarily poor prognosis owing to its difficulty in early diagnosis and complex treatments.Recently,great progress has been made in surgical techniques,adjuvant treatment and perioperative management of pancreatic cancer.However,the long-term survival of patients with pancreatic cancer has not been significantly improved. American Society of Clinical Oncology released clinical practice guidelines for potentially curable pancreatic cancer in 2016 and updated it for the first time in 2017.In2019,American Society of Clinical Oncology renewed its guidelines in order to modify the program of postoperative adjuvant therapy for pancreatic cancer and recommend FOLFIRINOX as the first choice for postoperative adjuvant therapy for patients with pancreatic cancer in order to improve the prognosis of patients with pancreatic cancer.
RESUMO
Microcystic meningioma, a distinct morphological variant of meningiomas, is histologically characterized by a vacuolated appearance with multiple cystic spaces lined by vacuolated or stellate-shaped tumor cells. This unusual variant was originally described by Masson, who labeled it "humid". The clinical and morphological findings point toward a benign course. And these unusual morphological variants of meningioma are potentially curable tumor. But there is no definitive method for preoperatively differentiating microcystic meningioma from the malignant glioma. We report a case of microcystic meningioma occurring in the left frontal area of 74 year old woman, with malignant clinical nature.